PTD-DBM vs Acetyl Tetrapeptide-5
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Eyeseryl, Ac-beta-Ala-His-Ser-His
Acetyl tetrapeptide-5 is a short synthetic peptide sold by Lipotec (now Lubrizol) as Eyeseryl, made for eye creams that target under-eye puffiness. The pitch is that it reduces fluid leaking into the tissue under the eyes. It is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Acetyl Tetrapeptide-5 (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | Acetyl Tetrapeptide-5 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | The peptide is acetyl-beta-alanine-histidine-serine-histidine. The manufacturer's lab work claims three effects: it reduces vascular permeability (less fluid seeping out of small blood vessels, tested in an endothelial cell model), it inhibits glycation (sugar damage to proteins like collagen), and it has some ACE-inhibiting activity that is linked to fluid balance. All of that is in vitro and company-generated. An important reality check: under-eye bags have several causes, and a lot of them in older adults come from fat pads pushing forward and loose skin, not fluid. A peptide aimed at fluid cannot touch fat-pad bags, so even in the best case it fits morning puffiness better than structural eye bags. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | 1% of the Eyeseryl solution in an eye cream Twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (eye creams, gels, serums) |
| Typical Duration | Applied over several weeks in animal studies | 28-60 days in manufacturer studies; ongoing use to maintain any effect |
| Best Time to Take | Not established (topical in animal studies) | Morning and evening, gently patted under the eyes |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | We could not find an independent, peer-reviewed clinical trial of acetyl tetrapeptide-5. The evidence is manufacturer data reported in trade publications. Lipotec's best-known study used a 1% Eyeseryl cream on one eye and placebo on the other in male volunteers aged 30 to 65, twice daily for 28 days, and reported about a 30% reduction in under-eye puffiness volume, with most volunteers rating it positively. Another supplier document describes a 60-day study in 20 women using a cream with a very low peptide level, scored from photos by a dermatologist. Other summaries quote different numbers (17% to 21%) from studies we could not trace to an original paper. The studies differ in concentration, sex, length and how puffiness was measured, so they cannot be pooled. Independent ingredient databases rate the evidence as limited for exactly this reason. Bottom line: plausible for mild fluid puffiness, cheap to try in an eye cream, but not a fix for true eye bags and not backed by independent trials. |
Frequently Asked Questions: PTD-DBM vs Acetyl Tetrapeptide-5
What is the difference between PTD-DBM and Acetyl Tetrapeptide-5?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. Acetyl Tetrapeptide-5 is a skin & hair peptide that acetyl tetrapeptide-5 is a short synthetic peptide sold by lipotec (now lubrizol) as eyeseryl, made for eye creams that target under-eye puffiness. the pitch is that it reduces fluid leaking into the tissue under the eyes. it is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or Acetyl Tetrapeptide-5?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while Acetyl Tetrapeptide-5 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and Acetyl Tetrapeptide-5 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and Acetyl Tetrapeptide-5 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.